Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L. Gérard JP, et al. Among authors: closon dejardin mt. J Clin Oncol. 2006 Oct 1;24(28):4620-5. doi: 10.1200/JCO.2006.06.7629. J Clin Oncol. 2006. PMID: 17008704 Clinical Trial.
Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study.
de Azambuja E, Paesmans M, Beauduin M, Vindevoghel A, Cornez N, Finet C, Ries F, Closon-Dejardin MT, Kerger J, Gobert P, Focan C, Tagnon A, Dolci S, Nogaret JM, di Leo A, Piccart-Gebhart MJ. de Azambuja E, et al. Among authors: closon dejardin mt. J Clin Oncol. 2009 Feb 10;27(5):720-5. doi: 10.1200/JCO.2008.17.2155. Epub 2008 Dec 22. J Clin Oncol. 2009. PMID: 19103732 Clinical Trial.
Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.
Piccart MJ, Di Leo A, Beauduin M, Vindevoghel A, Michel J, Focan C, Tagnon A, Ries F, Gobert P, Finet C, Closon-Dejardin MT, Dufrane JP, Kerger J, Liebens F, Beauvois S, Bartholomeus S, Dolci S, Lobelle JP, Paesmans M, Nogaret JM. Piccart MJ, et al. Among authors: closon dejardin mt. J Clin Oncol. 2001 Jun 15;19(12):3103-10. doi: 10.1200/JCO.2001.19.12.3103. J Clin Oncol. 2001. PMID: 11408507 Clinical Trial.
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
Di Leo A, Larsimont D, Gancberg D, Jarvinen T, Beauduin M, Vindevoghel A, Michel J, Focan CH, Ries F, Gobert PH, Closon-Dejardin MT, Dolci S, Rouas G, Paesmans M, Lobelle JP, Isola J, Piccart MJ. Di Leo A, et al. Among authors: closon dejardin mt. Ann Oncol. 2001 Aug;12(8):1081-9. doi: 10.1023/a:1011669223035. Ann Oncol. 2001. PMID: 11583189 Free article. Clinical Trial.
Recurrence dynamics of breast cancer according to baseline body mass index.
Biganzoli E, Desmedt C, Fornili M, de Azambuja E, Cornez N, Ries F, Closon-Dejardin MT, Kerger J, Focan C, Di Leo A, Nogaret JM, Sotiriou C, Piccart M, Demicheli R. Biganzoli E, et al. Among authors: closon dejardin mt. Eur J Cancer. 2017 Dec;87:10-20. doi: 10.1016/j.ejca.2017.10.007. Epub 2017 Oct 31. Eur J Cancer. 2017. PMID: 29096156 Clinical Trial.
[Treatment of breast cancer. Our stance in 1986].
Bradfer J, Bury J, Closon J, Closon-Dejardin MT, Colin C, Crevecoeur M, Desaive C, Duvivier J, Fissette J, Focan C, et al. Bradfer J, et al. Among authors: closon dejardin mt. Rev Med Liege. 1987 Feb 15;42(4):121-30. Rev Med Liege. 1987. PMID: 3550995 Review. French. No abstract available.